Shares of Immutep Limited (NASDAQ:IMMP - Get Free Report) passed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $2.27 and traded as low as $2.04. Immutep shares last traded at $2.08, with a volume of 92,980 shares.
Wall Street Analysts Forecast Growth
Separately, Robert W. Baird reduced their target price on shares of Immutep from $7.00 to $6.00 and set an "outperform" rating for the company in a research report on Thursday, June 27th.
View Our Latest Research Report on IMMP
Immutep Price Performance
The stock's fifty day moving average price is $2.27 and its two-hundred day moving average price is $2.42.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in IMMP. XY Capital Ltd acquired a new position in Immutep during the second quarter valued at approximately $105,000. Oracle Investment Management Inc. lifted its holdings in shares of Immutep by 9.4% during the 1st quarter. Oracle Investment Management Inc. now owns 564,879 shares of the biotechnology company's stock valued at $1,316,000 after acquiring an additional 48,449 shares in the last quarter. Virtu Financial LLC boosted its position in Immutep by 269.4% during the 1st quarter. Virtu Financial LLC now owns 45,062 shares of the biotechnology company's stock worth $105,000 after purchasing an additional 32,864 shares during the period. XTX Topco Ltd acquired a new stake in Immutep in the 2nd quarter valued at $26,000. Finally, BNP Paribas Financial Markets raised its position in Immutep by 15.4% in the first quarter. BNP Paribas Financial Markets now owns 35,300 shares of the biotechnology company's stock valued at $82,000 after purchasing an additional 4,700 shares during the period. Institutional investors and hedge funds own 2.32% of the company's stock.
About Immutep
(
Get Free Report)
Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.
Featured Articles
Before you consider Immutep, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immutep wasn't on the list.
While Immutep currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
